Apart from its prognostic implications, our observations revealed an association between MrgD expression and a poorer response to TKIs, antiangiogenic drugs that represent the first therapeutic line for advanced CCRCC together with immune checkpoint inhibitors (ICIs) [30]. Here, MRGPRD is linked to nonpapillary renal cell carcinoma.